Iranian Red Crescent Medical Journal (IRCMJ)

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

Journal Metrics

News

Author Guidelines

Article Processing Charge

Effect of a Combinational therapy of Erythropoietin, Pentoxifylline, and Vitamin D on the Glasgow Outcome Scale in Patients with Traumatic Brain Injury

Document Type : Research articles

Authors

1 Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

2 Department of Neurosurgery and brain surgery, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

3 Department of Neurosurgery, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

Abstract

Background: Diffuse axonal injury (DAI) is the most prevalent nerve lesion in brain trauma. Given the known effects of erythropoietin and pentoxifylline on the reduction of cell death following hypoxia.
Objectives: The current study assessed the possible effects of a combination of erythropoietin, pentoxifylline, and vitamin D on patients' consciousness level.
Methods: The present research is a double-blind clinical trial with parallel groups addressing 64 DAI patients (average age: 26.5). The intervention group included 32 patients who, apart from the routine treatment, received a combination of erythropoietin, pentoxifylline, and vitamin D3. The control group also encompassed 32 patients who only received routine treatment. The effects of the interventions were assessed based on Glasgow Coma Scale (GCS), Glasgow Outcome Scale (GOS) scores, and hospitalization duration.
Results: The findings of the current research revealed that the GCS scores of the supplement (13.6±0.5) and control groups (12.4±1.6) were significantly different (P=0.043), being higher in the supplement group. The supplement group gained a higher GOS score compared to the controls (4.62±0.15 and 3.8±0.16, respectively, P=0.045). Moreover, a significant difference was observed in the hospitalization duration of the supplement (26.5±5.2) and control groups (21.4±3.2) (P=0.020). Nonetheless, the analysis of the extubation time and blood pressure of the two groups exhibited no substantial difference.
Conclusion: In this study, GCS and GOS improved after supplementation. The patients in the supplement group displayed a significantly shorter hospitalization duration. No significant difference was, however, detected when the tube was removed.

Keywords

References
  1. Menon DK, Schwab K, Wright DW, Maas AI. Position statement: definition of traumatic brain injury. Arch Phys Med Rehabil. 2010;91(11):1637-40. doi: 10.1016/j.apmr.2010.05.017. [PubMed: 21044706].
  2. Hyder AA, Wunderlich CA, Puvanachandra P, Gururaj G, Kobusingye OC. The impact of traumatic brain injuries: a global perspective. NeuroRehabilitation. 2007;22(5):341-53. [PubMed: 18162698].
  3. Feigin VL, Theadom A, Barker-Collo S, Starkey NJ, McPherson K, Kahan M, et al. Incidence of traumatic brain injury in New Zealand: a population-based study. Lancet Neurol. 2013;
  4. (1):53-64. doi: 10.1016/S1474-4422(12)70262-4. [PubMed: 23177532].
  5. Faul M, Wald MM, Xu L, Coronado VG. Traumatic brain injury in the United States; emergency department visits, hospitalizations, and deaths, 2002-2006. CDC; 2010.
  6. Gentleman D. Preventing secondary brain damage after head injury: a multidisciplinary challenge. Injury. 1990;21(5):305-8. doi: 10.1016/0020-1383(90)90047-x. [PubMed: 2242917].
  7. Matthews DS, Matthews JN, Aynsley-Green A, Bullock RE, Eyre JA. Changes in cerebral oxygen consumption are independent of changes in body oxygen consumption after severe head injury in childhood. J Neurol Neurosurg Psychiatry. 1995;59(4):359-67. doi: 10.1136/jnnp.59.4.359. [PubMed: 7561912].
  8. Feng D, Ma Y, Zhang Y, Plets C, Goffin J, Chen J. Controlled study of nimodipine in treatment of patients with diffuse axonal injury. Chin J Traumatol. 2000;3(2):85-8. [PubMed: 11874647].
  9. Liu WC, Wen L, Xie T, Wang H, Gong JB, Yang XF. Therapeutic effect of erythropoietin in patients with traumatic brain injury: a meta-analysis of randomized controlled trials. J Neurosurg. 2016;127(1):8-15. doi: 10.3171/2016.4.JNS152909. [PubMed: 27367243].
  10. Goksu E, Dogan O, Ulker P, Tanrıover G, Konuk E, Dilmac S, et al. Pentoxifylline alleviates early brain injury in a rat model of subarachnoid hemorrhage. Acta Neurochir (Wien). 2016;
  11. (9):1721-30. doi: 10.1007/s00701-016-2866-5. [PubMed: 27311763].
  12. Abrishamkar S, Safavi M, Honarmand A. Effect of erythropoietin on Glasgow Coma Scale and Glasgow Outcome Sale in patient with diffuse axonal injury. J Res Med Sci. 2012;17(1):51-6. [PubMed: 23248657].
  13. Stein DG. Embracing failure: what the phase III progesterone studies can teach about TBI clinical trials. Brain Inj. 2015;29(11):1259-72. doi: 10.3109/02699052.2015.1065344. [PubMed: 26274493].
  14. Daneshvar DH, Goldstein LE, Kiernan PT, Stein TD, McKee AC. Post-traumatic neurodegeneration and chronic traumatic encephalopathy. Mol Cell Neurosci. 2015;66:81-90. doi: 10.1016/j.mcn.2015.03.007. [PubMed: 25758552].
  15. Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M, et al. The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol. 2003;62(3):228-36. doi: 10.1093/jnen/62.3.228. [PubMed: 12638727].
  16. Campana WM, Myers RR. Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. FASEB J. 2001;15(10):1804-6. doi: 10.1096/fj.00-0857fje. [PubMed: 11481236].
  17. Grasso G. Neuroprotective effect of recombinant human erythropoietin in experimental subarachnoid hemorrhage. J Neurosurg Sci. 2001;45(1):7-14. [PubMed: 11466502].
  18. Lykissas MG, Korompilias AV, Vekris MD, Mitsionis GI, Sakellariou E, Beris AE. The role of erythropoietin in central and peripheral nerve injury. Clin Neurol Neurosurg. 2007;109(8):639-44. doi: 10.1016/j.clineuro.2007.05.013. [PubMed: 17624659].
  19. Yatsiv I, Grigoriadis N, Simeonidou C, Stahel PF, Schmidt OI, Alexandrovich AG, et al. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J. 2005;19(12):1701-3. doi: 10.1096/fj.05-3907fje. [PubMed: 16099948].
  20. Talving P, Lustenberger T, Inaba K, Lam L, Mohseni S, Chan L, et al. Erythropoiesis-stimulating agent administration and survival after severe traumatic brain injury: a prospective study. Arch Surg. 2012;147(3):251-5. doi: 10.1001/archsurg.2011.1838. [PubMed: 22430906].
  21. Tsai TH, Lu CH, Wallace CG, Chang WN, Chen SF, Huang CR, et al. Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trial. Crit Care. 2015;19(1):1-9. doi: 10.1186/s13054-015-0761-8. [PubMed: 25888250].
  22. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8(8):495-505. [PubMed: 12435860].
  23. Nichol A, French C, Little L, Haddad S, Presneill J, Arabi Y, et al. Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial. Lancet. 2015;386(10012):2499-506. doi: 10.1016/S0140-6736(15)00386-4. [PubMed: 26452709].
  24. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al. Recombinant human erythropoietin
  25. in the treatment of acute ischemic stroke. Stroke. 2009;40(12):647-56. doi: 10.1161/STROKEAHA.109.564872. [PubMed: 19834012].
  26. Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A. 2002;99(14):9450-5. doi: 10.1073/pnas.142287899. [PubMed: 12082184].
  27. Doyle J, Creager MA. Pharmacotherapy and behavioral intervention for peripheral arterial disease. Rev Cardiovasc Med. 2003;4(1):18-24.
  28. Vakili A, Mojarrad S, Akhavan MM, Rashidy-Pour A. Pentoxifylline attenuates TNF-α protein levels and brain edema following temporary focal cerebral ischemia in rats. Brain
  29. Res. 2011;1377:119-25. doi: 10.1016/j.brainres.2011.01.001. [PubMed: 21219888].
  30. Neves KRT, Nobre Jr HV, Leal LKA, de Andrade GM, de Castro Brito GA, de Barros Viana GS. Pentoxifylline neuroprotective effects are possibly related to its anti-inflammatory and TNF-alpha inhibitory properties, in the 6-OHDA model of Parkinson's disease. Parkinsons Dis. 2015;2015:1-15. doi: 10.1155/2015/108179. [PubMed: 26491600].
  31. Bowton DL, Stump DA, Prough DS, Toole JF, Lefkowitz DS, Coker L. Pentoxifylline increases cerebral blood flowin patients with cerebrovascular disease. Storke. 1989;20(12):1662-6. doi: 10.1161/01.str.20.12.1662. [PubMed: 2512690].
  32. Bhat AR, Wani MA, Kirmani A, Raina T, Alam S, Ramzan A. Traumatic brain edema and survival-effective role of pentoxifylline. Biomed Res J. 2008;19(3):161-7.
  33. Cekic M, Cutler SM, VanLandingham JW, Stein DG. Vitamin D deficiency reduces the benefits of progesterone treatment
  34. after brain injury in aged rats. Neurobiol Aging.
  35. ;32(5):864-74. doi: 10.1016/j.neurobiolaging.2009.04.017. [PubMed: 19482377].
  36. Atif F, Yousuf S, Sayeed I, Ishrat T, Hua F, Stein DG. Combination treatment with progesterone and vitamin D hormone is more effective than monotherapy in ischemic stroke: the role of BDNF/TrkB/Erk1/2 signaling in neuroprotection. Neuropharmacology. 2013;67:78-87. doi: 10.1016/j.neuropharm.2012.10.004. [PubMed: 23154302].
  37. Arabi SM, Sedaghat A, Ehsaei MR, Safarian M, Ranjbar G, Rezaee H, et al. Efficacy of high-dose versus low-dose vitamin D supplementation on serum levels of inflammatory factors and mortality rate in severe traumatic brain injury patients: study protocol for a randomized placebo-controlled trial. Trials. 2020;21(1):1-8. doi: 10.1186/s13063-020-04622-6.
  38. Lee JM, Jeong SW, Kim MY, Park JB, Kim MS. The effect of vitamin D supplementation in patients with acute traumatic brain injury. World Neurosurg. 2019;126:1421-6. doi: 10.1016/j.wneu.2019.02.244. [PubMed: 30904798].
  39. Evans MA, Kim HA, Ling YH, Uong S, Vinh A, De Silva TM, et al. Vitamin D 3 supplementation reduces subsequent brain injury and inflammation associated with ischemic stroke. Neuromolecular Med. 2018;20(1):147-59. doi: 10.1007/s12017-018-8484-z. [PubMed: 29476479].
  40. Fu J, Xue R, Gu J, Xiao Y, Zhong H, Pan X, et al. Neuroprotective effect of calcitriol on ischemic/reperfusion injury through the NR3A/CREB pathways in the rat hippocampus. Mol Med Rep. 2013;8(6):1708-14. doi: 10.3892/mmr.2013.1734. [PubMed: 24141895].
  41. Colon YM. Vitamin D clinical relevance in the recovery from traumatic brain injury among the military population. [Thesis]. University of Central Florida; 2016.
Iranian Red Crescent Medical Journal (IRCMJ)
Volume 24, Issue 9 - Serial Number 9
2022
Files
History
  • Receive Date: 09 August 2021
  • Revise Date: 23 May 2024
  • Accept Date: 27 January 2024
  • First Publish Date: 27 January 2024
  • Publish Date: 01 September 2022
Share
How to cite
Statistics